TD001 / T.O.A.D. Oncology - LARVOL DELTA

Improved tumor penetration and cytotoxic payload release with TD001, a novel PSMA-targeting ADC with optimized linker-payload composition, in PSMA-expressing CRPC CDX castrated mouse models (AACR 2025) - "Notably, tumor uptake and a very high tumor/plasma ratio (70-100 fold) of exatecan were similar 24 h after IV administration in all three in vivo models despite substantial differences in PSMA expression and heterogeneity. These findings highlight the ability of TD001 to deliver effectively and selectively the payload exatecan to PSMA-positive prostate tumors, resulting in potent antitumor activity in different CRPC models, including those with intermediate and heterogenous PSMA expression."

ADC • Preclinical • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • AR • CASP3 • FOLH1

Dose-response and tumor size at time of treatment with TD001, a novel ADC against PSMA, drive potent tumor growth inhibition in a CRPC CDX castrated mouse model (AACR 2025) - "Pharmacokinetics/pharmacodynamic correlations of TD001 are described separately. TD001 appears as a best-in-class anti-PSMA Topo I inhibitor ADC (exatecan payload), and exhibited potent and sustained antitumor activity, including in large tumors, and represents a promising new treatment for PSMA-expressing CRPC patients."

ADC • Preclinical • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • FOLH1

Optimal free exatecan payload tumor/plasma ratio of TD001, a new ADC against PSMA, in CRPC CDX mouse models (AACR 2025) - "TD001 effectively and preferentially delivers the potent exatecan payload to tumor tissue, with minimal systemic exposure, contributing to an excellent therapeutic index and strong antitumor activity in multiple CRPC models with high or intermediate PSMA expression. Our preclinical PK data support clinical development of TD001 in PSMA-expressing CRPC patients."

ADC • Preclinical • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • FOLH1

Long-term tumor growth inhibition and extended survival with TD001, a novel optimized PSMA-targeting ADC, in PSMA-expressing CRPC CDX castrated mouse models (AACR 2025) - "TD001 appears as a best-in-class anti-PSMA ADC with its novel linker-payload (LD038) and exhibits potent antitumor activity in preclinical models with a broad range of PSMA expression, representing a highly promising treatment for PSMA-expressing CRPC patients. The efficacy of TD001 in preclinical in vivo castrated CDX and PDX models supports further investigation in clinical settings."

ADC • Preclinical • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • FOLH1

TD001-101: A first-in-human study to determine a safe dose of the drug TD001 to treat patients with metastatic prostate cancer that expresses the PSMA protein. (clinicaltrialsregister.eu) - P1/2 | N=110 | Recruiting | Sponsor: T.O.A.D. Oncology S.A.

First-in-human • New P1/2 trial • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • HRD

A Clinical Trial Evaluating the Safety of TD001 In Patients With PSMA-Expressing Metastatic Prostate Cancer (clinicaltrials.gov) - P1/2 | N=180 | Recruiting | Sponsor: T.O.A.D. Oncology SA | Not yet recruiting ➔ Recruiting

Enrollment open • First-in-human • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

A Clinical Trial Evaluating the Safety of TD001 In Patients With PSMA-Expressing Metastatic Prostate Cancer (clinicaltrials.gov) - P1/2 | N=180 | Not yet recruiting | Sponsor: T.O.A.D. Oncology SA

New P1/2 trial • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor